Anda belum login :: 20 Apr 2025 17:01 WIB
Detail
ArtikelEffect of Ingested Interferon-a on ß-Cell Function in Children With New-Onset Type 1 Diabetes  
Oleh: Rother, Kristina I. ; Brown, Rebecca J. ; Morales, Miriam M. ; Wright, Elizabeth
Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 32 no. 07 (Jul. 2009), page 1250-1255.
Topik: Ingested Interferon-a on ß-Cell Function; Children With New-Onset Type 1 Diabetes
Ketersediaan
  • Perpustakaan FK
    • Nomor Panggil: D05.K.2009.02
    • Non-tandon: 1 (dapat dipinjam: 0)
    • Tandon: tidak ada
    Lihat Detail Induk
Isi artikelOBJECTIVE : To evaluate the safety and efficacy of ingested human recombinant interferon-a (hrIFN-a) for preservation of ß-cell function in young patients with recent-onset type 1 diabetes. RESEARCH DESIGN AND METHODS : Subjects aged 3–25 years in whom type 1 diabetes was diagnosed within 6 weeks of enrollment were randomly assigned to receive ingested hrIFN-a at 5,000 or 30,000 units or placebo once daily for 1 year. The primary outcome was change in C-peptide secretion after a mixed meal. RESULTS : Individuals in the placebo group (n = 30) lost 56 ± 29% of their C-peptide secretion from 0 to 12 months, expressed as area under the curve (AUC) in response to a mixed meal. In contrast, children treated with hrIFN-a lost 29 ± 54 and 48 ± 35% (for 5,000 [n = 27] and 30,000 units [n = 31], respectively, P = 0.028, ANOVA adjusted for age, baseline C-peptide AUC, and study site). Bonferroni post hoc analyses for placebo versus 5,000 units and placebo versus 30,000 units demonstrated that the overall trend was determined by the 5,000-unit treatment group. Adverse events occurred at similar rates in all treatment groups. CONCLUSIONS : Ingested hrIFN-a was safe at the doses used. Patients in the 5,000-unit hrIFN-a treatment group maintained more ß-cell function 1 year after study enrollment than individuals in the placebo group, whereas this effect was not observed in patients who received 30,000 units hrIFN-a. Further studies of low-dose ingested hrIFN-a in new-onset type 1 diabetes are needed to confirm this effect.
Opini AndaKlik untuk menuliskan opini Anda tentang koleksi ini!

Kembali
design
 
Process time: 0.015625 second(s)